Sanofi Genzyme goes to Phase III with Neuromuscular Disease
FDA approves Sanofi's Nexviazyme for Pompe disease treatment
Sanofi su LinkedIn: Malattia di Fabry
Sanofi Genzyme: COMET Phase 3 Trial - Results | Pompe Support Network
Sanofi finds new Pompe disease therapy in Maze | pharmaphorum
DottNet - Malattia di Pompe: priority review della FDA per avalglucosidasi alfa
MeetSanofi | Malattia di Pompe, la qualità della vita passa anche dal cibo e dalla tecnologia
Sanofi pumps up its Pompe portfolio with Maze deal | Evaluate
Sanofi Launched Advanced Treatment for Pompe Disease | CCI France Taiwan
Sanofi extends its Pompe range with first Nexviazyme OK | pharmaphorum
U.S. FDA approves another Sanofi drug for rare muscle disorder Pompe disease | Reuters
Sanofi's enzyme replacement therapy available on NHS to Pompe disease patients - PMLiVE
Sanofi signs agreement worth up to $750m for Maze's Pompe disease drug
Sanofi stock rises on licensing deal with Maze for Pompe disease drug | Seeking Alpha
Sanofi CEO does not rule out future Pompe BD despite FTC moves
Sanofi invests US$150m to acquire oral Pompe disease drug candidate from Maze Therapeutics | HealthCare Middle East & Africa Magazine
Sanofi coughs up $180M to settle Pompe disease royalty payment dispute | Fierce Pharma
Sanofi Finds Way to Maze Therapeutics to Get Its Next Pompe Disease Drug - MedCity News
Malattia di Pompe a esordio tardivo in età pediatrica - Premio Eccellenze dell'Informazione Scientifica
Sanofi US on X: "Have you heard of #Pompe disease? Just knowing the symptoms of this #RareDisease could help reduce the time to diagnosis. Share with the hashtag #GreaterThanPompe to raise awareness
FDA approves Sanofi's Nexviazyme for late-onset Pompe disease - Drug Discovery and Development
